Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:0
  • preuzimanja u poslednjih 30 dana:0

Sadržaj

članak: 4 od 41  
Back povratak na rezultate
2018, vol. 75, br. 6, str. 604-610
Promet i funkcija trombocita u završnom stadijumu hronične bubrežne insuficijencije
aKlinički centar Vojvodine, Centar za laboratorijsku medicinu, Novi Sad
bKlinički centar Vojvodine, Klinika za nefrologiju i kliničku imunologiju, Novi Sad + Univerzitet u Novom Sadu, Medicinski fakultet
cKlinički centar Vojvodine, Centar za laboratorijsku medicinu, Novi Sad + Univerzitet u Novom Sadu, Medicinski fakultet

e-adresadrfilbuzzgroup7@yahoo.com
Sažetak
Uvod/Cilj. Završni stadijum hronične bubrežne insuficijencije [ nd-stage renal disease (ESRD)] karakteriše prisustvo značajnog oštećenja trombocitnih funkcija koje mogu dovesti do krvarećih i tromboznih komplikacija. Cilj rada bio je procena prometa i funkcionalnosti trombocita i korelacija sa zapaljenskim i prokoagulantnim markerima kod bolesnika sa ESRD, kao i poređenje trombocitnih indeksa između bolesnika kod kojih je šećerna bolest etiološki faktor ESRD i bolesnika sa ESRD druge etiologije. Metode. U prospektivno opservaciono kliničko istraživanje uključeno je 63 ispitanika sa ESRD i 30 zdravih osoba usklađenih po starosti i po polu (kontrolna grupa). Određivani su laboratorijski parametri prometa i funkcionalnosti trombocita (broj trombocita, retikulisani trombociti, trombocitni indeksi i agregabilnost trombocita merena impendancom iz pune krvi), zapaljenski i prokoagulantni markeri (broj neutrofila, odnos neutrofila i limfocita, C-reaktivni protein, fibrinogen, D dimer, von Willebrand-ov faktor). Rezultati. U grupi ispitanika sa ESRD u poređenju sa grupom zdravih, promet trombocita (% retikulisanih trombocita) je bio statistički značajno veći (3,8 ± 2,3 vs. 2,3 ± 1,3; p < 0,01), kao i agregabilnost trombocita indukovana sa trombin receptor-aktivirajućim peptidom (TRAP) (p < 0,01), adenozin-difosatom (ADP) (p < 0,05), arahidonskom kiselinom (ASPI) (p < 0,05) i kolagenom (p < 0,05). U ESRD grupi su potvrđene značajno više vrednosti svih zapaljenskih i prokoagulantnih markera u odnosu na zdrave ispitanike (p < 0,01, za sve parametre). Nije utvrđena razlika u ispitivanim parametrima između grupe bolesnika kod kojih je šećerna bolest uzročnik ESRD i grupe bolesnika sa ESRD druge etiologije. Zaključak. Rezultati pokazuju da je povišen promet trombocita u ESRD posledica njihove aktivacije i potrošnje indukovane hiperaktivnošću koagulacionog sistema i hroničnim zapaljenjem. Nijedan od ispitivanih parametara ne predviđa mogućnost pojave krvarenja.
Reference
Abe, Y., Wada, H., Tomatsu, H., Sakaguchi, A., Nishioka, J., Yabu, Y., Onishi, K., Nakatani, K., Morishita, Y., Oguni, S., Nobori, T. (2006) A simple technique to determine thrombopoiesis level using immature platelet fraction (IPF). Thrombosis Research, 118(4): 463-469
Adams, M.J., Irish, A.B., Watts, G.F., Oostryck, R., Dogra, G.K. (2008) Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function. Thrombosis Research, 123(2): 374-380
Astrup, T. (1958) The Haemostatic Balance)). Thrombosis and Haemostasis, 02(01): 347-357
Boccardo, P., Remuzzi, G., Galbusera, M. (2004) Platelet Dysfunction in Renal Failure. Seminars in Thrombosis and Hemostasis, 30(5): 579-589
Casserly, L.F., Dember, L.M. (2003) Thrombosis in End-Stage Renal Disease. Seminars in Dialysis, 16(3): 245-256
Darlington, A., Luis, F.J., Ueno, M., Suzuki, Y., Desai, B., Capranzano, P., Capodanno, D., Tello-Montoliu, A., Bass, T.A., Nahman, N.S., Angiolillo, D.J. (2011) Haemostatic profiles assessed by thromboelastography in patients with end-stage renal disease. Thrombosis and Haemostasis, 106(07): 67-74
Dusse, L.M.S., Freitas, L.G. (2015) Clinical applicability of reticulated platelets. Clinica Chimica Acta, 439: 143-147
Escolar, G., Diaz-Ricart, M. (2005) Uremic platelet dysfunction: past and present. Curr Hematol Rep, 4(5): 359-67
Forbes, S., Ashman, N., Yaqoob, M. (2013) The role of platelets in the prognosis of renal disease. OA Nephrology, 1(2): 17
Fox, C.S., Larson, M.G., Leip, E.P., Culleton, B., Wilson, P.W.F., Levy, D. (2004) Predictors of new-onset kidney disease in a community-based population. JAMA, 291(7): 844-50
Gafter, U., Bessler, H., Malachi, T., Zevin, D., Djaldetti, M., Levi, J. (2008) Platelet Count and Thrombopoietic Activity in Patients with Chronic Renal Failure. Nephron, 45(3): 207-210
Glorieux, G., Cohen, G., Jankowski, J., Vanholder, R. (2009) Platelet/Leukocyte Activation, Inflammation, and Uremia. Seminars in Dialysis, 22(4): 423-427
Go, A.S., Chertow, G.M., Fan, D., McCulloch, C.E., Hsu, C. (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med, 351(13): 1296-305
Grove, E.L. (2012) Antiplatelet effect of aspirin in patients with coronary artery disease. Dan Med J, 59(9): B4506
Ho, S., Gemmell, R., Brighton, T.A. (2008) Platelet function testing in uraemic patients. Hematology, 13(1): 49-58
Hoffmann, J.J. M. L., van den Broek, N.M. A., Curvers, J. (2013) Reference Intervals of Reticulated Platelets and Other Platelet Parameters and Their Associations. Archives of Pathology & Laboratory Medicine, 137(11): 1635-1640
Hoffmann, J.J.M.L. (2014) Reticulated platelets: analytical aspects and clinical utility. Clinical Chemistry and Laboratory Medicine (CCLM), 52(8): 1107-17
Jalal, D., Chonchol, M., Targher, G. (2010) Disorders of Hemostasis Associated with Chronic Kidney Disease. Seminars in Thrombosis and Hemostasis, 36(01): 034-040
Kakouros, N., Rade, J.J., Kourliouros, A., Resar, J.R. (2011) Platelet Function in Patients with Diabetes Mellitus: From a Theoretical to a Practical Perspective. International Journal of Endocrinology, 2011: 1-14
Keller, C., Katz, R., Cushman, M., Fried, L.F., Shlipak, M. (2008) Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: A cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrology, 9(1): 9
Kilickesmez, K.O., Kocas, C., Abaci, O., Okcun, B., Gorcin, B., Gurmen, T. (2013) Follow-up of aspirin-resistant patients with end-stage kidney disease. International Urology and Nephrology, 45(4): 1097-1102
Krentz, A.J. (2006) Diabetes, the kidney and vascular disease: a complex relationship. Practical Diabetes International, 23(1): 1-3
Leader, A., Pereg, D., Lishner, M. (2012) Are platelet volume indices of clinical use? A multidisciplinary review. Annals of Medicine, 44(8): 805-816
Levin, A. (2003) Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial, 16(2): 101-5
Libetta, C., Sepe, V., Esposito, P., Galli, F., Dal, C.A. (2011) Oxidative stress and inflammation: Implications in uremia and hemodialysis. Clinical Biochemistry, 44(14-15): 1189-1198
Małyszko, J., Małyszko, J.S., Myśliwiec, M., Buczko, W. (2005) Hemostasis in chronic renal failure. Rocz Akad Med Bialymst, 50: 126-31
Małyszko, J., Małyszko, J.S., Myśliwiec, M. (2004) Endothelial Cell Injury Markers in Chronic Renal Failure on Conservative Treatment and Continuous Ambulatory Peritoneal Dialysis. Kidney and Blood Pressure Research, 27(2): 71-77
Özkan, G., Ulusoy, Ş. (2013) Bleeding diathesis in hemodialysis patients. INTECH
Remuzzi, G. (1988) Bleeding in renal failure. Lancet, 331(8596): 1205-1208
Schoorl, M. (2016) Activation of platelets and coagulation during haemodialysis. Ned Tijdschr Klin Chem Labgeneesk, 41: 17-27
Shlipak, M. G. (2003) Elevations of Inflammatory and Procoagulant Biomarkers in Elderly Persons With Renal Insufficiency. Circulation, 107(1): 87-92
Sirolli, V., Ballone, E., Garofalo, D., Merciaro, G., Settefrati, N., di Mascio, R., di Gregorio, P., Bonomini, M. (2002) Platelet Activation Markers in Patients with Nephrotic Syndrome. Nephron, 91(3): 424-430
Stenvinkel, P. (2006) Inflammation in end-stage renal disease: The hidden enemy (Review Article). Nephrology, 11(1): 36-41
Turkmen, K., Guney, I., Yerlikaya, F.H., Tonbul, H.Z. (2012) The Relationship Between Neutrophil-to-Lymphocyte Ratio and Inflammation in End-Stage Renal Disease Patients. Renal Failure, 34(2): 155-159
van Bladel, E.R., de Jager, R.L., Walter, D., Cornelissen, L., Gaillard, C.A., Boven, L.A., Roest, M., Fijnheer, R. (2012) Platelets of patients with chronic kidney disease demonstrate deficient platelet reactivity in vitro. BMC Nephrology, 13(1): 127
Wattanakit, K., Cushman, M. (2009) Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms. Current Opinion in Pulmonary Medicine, 15(5): 408-412
Würtz, M., Wulff, L.N., Grove, E.L., Kristensen, S.D., Hvas, A. (2012) Influence of renal function and platelet turnover on the antiplatelet effect of aspirin. Thrombosis Research, 129(4): 434-440
Zwaginga, J. J. (2004) Hemodialysis, erythropoietin and megakaryocytopoiesis: factors in uremic thrombocytopathy and thrombophilia. Journal of Thrombosis and Haemostasis, 2(8): 1272-1274
 

O članku

jezik rada: engleski
vrsta rada: izvorni naučni članak
DOI: 10.2298/VSP160720374F
objavljen u SCIndeksu: 09.08.2018.
metod recenzije: dvostruko anoniman
Creative Commons License 4.0